Increased serum NfL and GFAP levels indicate different subtypes of neurologic immune‐related adverse events during treatment with immune checkpoint inhibitors

Documenti analoghi

• Serum NfL and GFAP as biomarkers of progressive neurodegeneration in TBI
  di: Pashtun Shahim, et al.
  Pubblicazione: (2024)
• Plasma NfL and GFAP for predicting VCID brain changes in the population
  di: Sheelakumari Raghavan, et al.
  Pubblicazione: (2024)
• Establishment of an animal model of immune‐related adverse events induced by immune checkpoint inhibitors
  di: Yuan Meng, et al.
  Pubblicazione: (2024)
• Tissue‐resident memory T cells in immunotherapy and immune‐related adverse events by immune checkpoint inhibitor
  di: Hao Xiong, et al.
  Pubblicazione: (2024)
• Immune‐related adverse events in immune checkpoint inhibitor therapy for cancer
  di: Katie Liao, et al.
  Pubblicazione: (2025)